Last reviewed · How we verify

Autologous cultured keratinocyte cell

Biosolution Co., Ltd. · Phase 3 active Small molecule

Autologous cultured keratinocyte cell is a Cell therapy Small molecule drug developed by Biosolution Co., Ltd.. It is currently in Phase 3 development for Severe burns, Chronic wounds, Diabetic ulcers. Also known as: Keraheal.

Autologous cultured keratinocytes are patient-derived skin cells grown in vitro and applied topically or as a graft to promote wound healing and tissue regeneration.

Autologous cultured keratinocytes are patient-derived skin cells grown in vitro and applied topically or as a graft to promote wound healing and tissue regeneration. Used for Severe burns, Chronic wounds, Diabetic ulcers.

At a glance

Generic nameAutologous cultured keratinocyte cell
Also known asKeraheal
SponsorBiosolution Co., Ltd.
Drug classCell therapy
ModalitySmall molecule
Therapeutic areaDermatology
PhasePhase 3

Mechanism of action

This cell therapy involves harvesting keratinocytes from a patient's own skin, expanding them in culture, and then delivering them back to the patient to cover wounds or damaged skin areas. The cells promote re-epithelialization, restore the skin barrier, and stimulate natural healing processes. This autologous approach minimizes immune rejection risk since the cells are derived from the patient themselves.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Autologous cultured keratinocyte cell

What is Autologous cultured keratinocyte cell?

Autologous cultured keratinocyte cell is a Cell therapy drug developed by Biosolution Co., Ltd., indicated for Severe burns, Chronic wounds, Diabetic ulcers.

How does Autologous cultured keratinocyte cell work?

Autologous cultured keratinocytes are patient-derived skin cells grown in vitro and applied topically or as a graft to promote wound healing and tissue regeneration.

What is Autologous cultured keratinocyte cell used for?

Autologous cultured keratinocyte cell is indicated for Severe burns, Chronic wounds, Diabetic ulcers.

Who makes Autologous cultured keratinocyte cell?

Autologous cultured keratinocyte cell is developed by Biosolution Co., Ltd. (see full Biosolution Co., Ltd. pipeline at /company/biosolution-co-ltd).

Is Autologous cultured keratinocyte cell also known as anything else?

Autologous cultured keratinocyte cell is also known as Keraheal.

What drug class is Autologous cultured keratinocyte cell in?

Autologous cultured keratinocyte cell belongs to the Cell therapy class. See all Cell therapy drugs at /class/cell-therapy.

What development phase is Autologous cultured keratinocyte cell in?

Autologous cultured keratinocyte cell is in Phase 3.

What are the side effects of Autologous cultured keratinocyte cell?

Common side effects of Autologous cultured keratinocyte cell include Infection at graft site, Graft failure or poor take, Scarring, Contracture.

Related